Sino Biological,Inc. (301047.SZ)
- Previous Close
69.85 - Open
68.68 - Bid 70.79 x --
- Ask 70.96 x --
- Day's Range
69.10 - 71.10 - 52 Week Range
56.60 - 103.68 - Volume
539,087 - Avg. Volume
552,415 - Market Cap (intraday)
9.167B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
35.30 - EPS (TTM)
2.01 - Earnings Date --
- Forward Dividend & Yield 2.00 (2.82%)
- Ex-Dividend Date May 24, 2023
- 1y Target Est
102.50
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers worldwide. It offers recombinant proteins, antibodies, cDNA clones, kits, and other reagents that are used in the areas of cancer, cardiovascular biology, cell and developmental biology, epigenetics, immunology, neuroscience, signal transduction, and stem cells. The company also provides pre-clinical production technology services for monoclonal antibody drug candidates; and custom services, such as protein production, antibody development and production, biological assay, and protein expression services. It serves academic research institutions, biotech companies, and pharmaceutical companies. The company was founded in 2016 and is headquartered in Beijing, China.
www.sinobiological.comRecent News: 301047.SZ
Performance Overview: 301047.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 301047.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 301047.SZ
Valuation Measures
Market Cap
9.17B
Enterprise Value
4.40B
Trailing P/E
35.24
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.18
Price/Book (mrq)
1.44
Enterprise Value/Revenue
6.81
Enterprise Value/EBITDA
12.18
Financial Highlights
Profitability and Income Statement
Profit Margin
40.24%
Return on Assets (ttm)
1.29%
Return on Equity (ttm)
4.08%
Revenue (ttm)
646.39M
Net Income Avi to Common (ttm)
260.13M
Diluted EPS (ttm)
2.01
Balance Sheet and Cash Flow
Total Cash (mrq)
4.85B
Total Debt/Equity (mrq)
1.34%
Levered Free Cash Flow (ttm)
-870.88M
Research Analysis: 301047.SZ
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 301047.SZ
301047.SZ does not have Company Insights